document
provid
supplementari
inform
data
method
result
studi
estim
cost
vaccin
develop
epidem
infecti
diseas
supplement
compris
five
appendic
critic
companion
main
articl
shed
light
method
assumpt
data
sourc
across
stage
analysi
appendic
includ
appendix
acknowledg
appendix
eid
vaccin
r
pipelin
cost
research
method
appendix
statist
analysi
method
result
estim
vaccin
develop
project
cost
explanatori
factor
appendix
mont
carlo
simul
determin
r
cost
associ
current
vaccin
pipelin
structur
eid
appendix
stochast
optim
method
sensit
analysi
appendix
offer
acknowledg
organ
dedic
time
effort
respond
pipelin
cost
data
request
grate
appendix
present
detail
eid
vaccin
r
pipelin
cost
data
collect
methodolog
includ
present
addit
find
underpin
assumpt
behind
simul
stochast
optim
method
explain
appendic
supplement
begin
discuss
search
method
assumpt
underli
pipelin
research
process
includ
sourc
strategi
use
clean
valid
collect
data
turn
step
undertaken
collect
cost
inform
associ
eid
vaccin
r
pipelin
provid
detail
raw
data
find
assumpt
behind
step
pipelin
research
pipelin
research
compris
two
step
process
step
literatur
search
step
surveybas
valid
process
literatur
find
case
identif
new
candid
avail
public
sourc
final
eid
vaccin
r
pipelin
includ
studi
outcom
two
sequenti
step
constrain
follow
key
assumpt
serv
screen
criteria
pipelin
compil
process
vaccin
candid
would
need
direct
toward
human
use
vaccin
candid
would
need
classifi
follow
typolog
vaccin
technolog
provid
literatur
candid
demonstr
pure
passiv
immun
eg
monoclon
antibodi
would
consid
vaccin
vaccin
candid
would
consid
shown
minimum
immunogen
data
anim
model
vitro
studi
andor
comput
studi
avail
candid
would
disregard
gener
efficaci
data
show
complet
protect
candid
demonstr
efficaci
data
show
complet
protect
would
disregard
termin
safeti
reason
duplic
entri
candid
identifi
differ
literatur
sourc
survey
respond
basi
whether
candid
target
antigen
henc
diseas
candid
use
platform
technolog
develop
vaccin
candid
vaccin
candid
differ
one
three
criteria
report
survey
respond
also
consid
differ
vaccin
candid
demonstr
r
activ
publish
sourc
past
year
earlier
step
literatur
search
april
juli
collect
data
vaccin
r
pipelin
preclin
phase
iii
pathogen
deem
like
caus
sever
outbreak
near
futur
origin
dataset
larg
base
report
norwegian
institut
public
health
addit
expert
input
cepi
task
team
list
cepi
preliminari
busi
plan
mine
key
academ
literatur
januari
septemb
origin
pipelin
databas
updat
specif
appli
differ
search
strategi
follow
sourc
pubm
first
search
use
combin
two
search
option
field
term
vaccin
meshterm
name
diseas
second
search
name
eid
abstract
order
ensur
complet
search
effort
also
search
pipelin
inform
freeli
websit
press
releas
organ
identifi
vaccin
develop
partner
previou
literatur
search
scan
refer
list
identifi
articl
literatur
miss
vaccin
candid
previou
search
circul
list
vaccin
candid
includ
literatur
refer
member
cepi
scientif
advisori
committe
expert
confirm
addit
modif
previou
literatur
find
date
inform
made
avail
particular
candid
origin
volum
articl
identifi
variou
sourc
search
strategi
describ
identifi
articl
press
releas
onlin
materi
scope
associ
potenti
total
number
vaccin
candid
preclin
phase
iii
eid
see
refer
end
appendix
step
acknowledg
definit
current
product
pipelin
challeng
number
limit
inform
gather
includ
inform
public
avail
develop
may
wish
keep
inform
confidenti
inform
updat
regularli
public
avail
sourc
statu
product
develop
dynam
includ
partner
involv
develop
statu
order
address
limit
conduct
survey
valid
step
specif
septemb
januari
valid
previous
collat
eid
vaccin
r
pipelin
data
survey
sent
organ
identifi
directli
indirectli
eg
funder
collabor
partner
vaccin
project
owner
relev
eid
vaccin
r
previou
literatur
search
cover
vaccin
candid
identifi
step
survey
aim
captur
current
statu
develop
variou
vaccin
candid
identifi
literatur
identifi
potenti
new
vaccin
candid
inform
previous
made
publicli
avail
literatur
clarifi
inform
vaccin
candid
relat
diseas
focu
platform
technolog
use
product
develop
partner
sourc
fund
time
spent
timelin
project
bring
candid
preclin
phase
ii
stage
develop
cost
realiz
cost
project
bring
candid
preclin
phase
ii
stage
develop
driver
cost
timelin
risk
associ
vaccin
candid
develop
programm
receiv
survey
respons
organ
cover
vaccin
candid
eid
total
confirm
activ
yet
start
hold
vaccin
candid
due
lack
fund
previous
identifi
literatur
review
newli
report
vaccin
candid
vaccin
candid
concern
infecti
diseas
epidem
potenti
outsid
scope
prioriti
list
origin
set
vaccin
candid
identifi
literatur
prioriti
eid
remain
unspecifi
due
lack
respons
end
survey
confirm
termin
hold
due
technic
reason
confirm
activ
project
survey
respond
confirm
activ
yet
start
hold
due
lack
fund
reason
relat
technic
failur
step
cost
research
vaccin
eid
r
cost
data
inform
regress
simul
stochast
optim
analys
collect
survey
process
employ
valid
eid
r
pipelin
data
describ
step
pipelin
research
septemb
januari
launch
cost
data
collect
process
part
survey
describ
previou
section
copi
survey
access
follow
weblink
head
cepi
vaccin
r
pipelin
cost
track
survey
http
cepinetnew
vaccin
candid
confirm
survey
respons
vaccin
candid
report
full
r
cost
r
phase
definit
full
r
cost
includ
whether
report
cost
cover
critic
nonclin
clinic
chemistri
manufactur
control
cmc
regulatori
activ
associ
r
phase
classifi
r
scope
checklist
use
assess
complet
cost
estim
r
phase
see
appendix
tabl
detail
base
criterion
compil
initi
set
vaccin
candid
cost
entri
follow
sever
statist
test
describ
detail
appendix
merg
dataset
addit
cepi
data
vaccin
project
cost
gener
total
set
uniqu
vaccin
develop
project
cost
entri
includ
inform
r
phase
platform
technolog
diseas
indirect
cost
sector
affili
industri
versu
nonindustri
geograph
locat
product
develop
cost
estim
report
studi
includ
basic
laboratori
research
activ
eg
basic
epidemiolog
pathogen
biolog
studi
studi
antigen
detect
express
genet
construct
develop
new
anim
model
assist
vaccin
design
invitro
studi
develop
function
neutral
assay
immunoassay
etc
activ
associ
phase
iibiii
efficaci
test
cmc
regulatori
deliveri
activ
associ
stockpil
investig
materi
phase
iibiii
studi
activ
associ
manufactur
capac
build
mainten
support
phase
iibiii
studi
scale
product
respons
public
health
emerg
result
allow
us
merg
two
sampl
new
set
uniqu
cost
data
entri
cepi
cost
data
later
report
survey
respond
independ
therefor
remov
total
duplic
entri
final
dataset
check
allow
us
minim
risk
skew
increas
report
bia
baselin
data
use
determin
averag
vaccin
develop
project
cost
base
data
made
avail
us
construct
follow
variabl
assum
may
explanatori
role
determin
averag
vaccin
project
develop
cost
r
phase
r
timelin
year
indirect
cost
cost
may
includ
inkind
r
contribut
eg
train
develop
countri
scientist
share
compound
overhead
cost
includ
limit
build
run
cost
gener
administr
manag
cost
list
variabl
clearli
identifi
driver
pharmaceut
r
cost
numer
literatur
sourc
moreov
discuss
cost
driver
r
phase
survey
respond
commonli
cite
nonhuman
primat
studi
toxicolog
studi
analyt
test
manufactur
process
develop
project
manag
salari
consum
equip
clinic
trial
cost
associ
number
enrole
locat
studi
among
sever
common
reason
escal
cost
reason
unforeseen
regulatori
requir
also
argu
drive
vaccin
develop
project
cost
could
translat
quantifi
variabl
due
lack
suffici
inform
collect
via
survey
worth
note
consid
geograph
locat
product
develop
variabl
although
recogn
less
substanti
effect
r
cost
two
reason
first
almost
report
vaccin
r
project
includ
partner
multipl
countri
region
make
difficult
quantifi
relationship
geograph
locat
cost
second
sampl
size
larg
enough
accur
differenti
geographi
therefor
provid
signific
statist
infer
model
vaccin
project
cost
entri
clearli
attribut
low
middl
incom
countri
organ
prior
assess
statist
signific
construct
variabl
would
allow
us
conclud
whether
consid
explanatori
factor
averag
vaccin
develop
project
model
ran
descript
statist
assess
averag
distribut
report
data
variabl
appendix
appendix
box
plot
demonstr
distribut
report
cost
preclin
phase
ii
skew
upward
vaccin
develop
previou
vaccin
licensur
trackrecord
without
box
plot
wherea
rel
technolog
licens
vaccin
diseas
set
comparison
licens
vaccin
exist
box
plot
contrast
report
cost
preclin
phase
ii
distribut
toward
lower
end
diseas
licens
vaccin
exist
licens
vaccin
time
r
box
plot
industri
report
cost
distribut
similar
manner
nonindustri
report
estim
howev
industri
report
cost
includ
signific
outlier
higher
end
report
cost
rang
next
step
run
correl
test
determin
strongli
consid
variabl
relat
appendix
tabl
demonstr
weak
neg
correl
timelin
product
develop
licensur
trackrecord
weak
posit
correl
timelin
platform
technolog
licensur
trackrecord
find
suggest
timelin
like
somewhat
affect
level
experi
product
develop
undertak
vaccin
r
project
well
type
platform
technolog
use
develop
vaccin
signific
relationship
variabl
found
correl
coeffici
valu
close
zero
order
determin
whether
consid
variabl
statist
signific
explanatori
factor
averag
vaccin
develop
project
r
phase
ran
sever
regress
identifi
consist
signific
valu
confid
interv
although
variou
type
regress
model
potenti
use
present
find
linear
regress
use
ordinari
least
squar
ol
estim
explanatori
variabl
demonstr
coeffici
determin
r
squar
lowi
proport
varianc
averag
vaccin
develop
project
cost
r
phase
predict
explanatori
variabl
regress
model
coeffici
improv
run
nonlinear
eg
logarithm
exponenti
regress
also
test
howev
coeffici
improv
hierarch
cluster
data
therefor
opt
ol
wellestablish
method
robust
best
linear
unbias
estim
properti
conduct
hierarch
cluster
analysi
determin
extent
predict
cost
rang
model
fail
captur
proport
varianc
averag
vaccin
develop
project
cost
r
phase
predict
explanatori
variabl
regress
model
gener
linear
multipl
regress
function
analyt
purpos
express
follow
worth
note
regress
output
present
appendix
tabl
result
reliabl
given
signific
f
less
regress
howev
great
deal
variat
averag
cost
estim
suffici
explain
standalon
combin
consid
explanatori
variabl
r
squar
less
regress
multipl
r
squar
less
regress
larg
residu
valu
therefor
ran
hierarch
cluster
analysi
identifi
potenti
cluster
cost
estim
sampl
associ
cost
driver
captur
test
variabl
could
improv
explanatori
power
model
comput
distanc
cluster
use
euclidean
metric
similar
measur
data
result
present
appendix
dendrogram
appendix
tabl
vertic
distanc
subclust
dendrogram
show
strong
cluster
effect
becom
immedi
appar
test
cluster
preclin
cost
level
appendix
dendrogram
subclust
contain
observ
subclust
singl
observ
subclust
observ
contain
remain
subclust
whose
distanc
cost
term
small
similarli
test
cluster
clinic
cost
level
appendix
dendrogram
subclust
concern
singl
observ
wherea
observ
contain
remain
subclust
whose
distanc
cost
term
small
base
find
present
appendix
product
develop
licensur
trackrecord
indirect
cost
signific
explanatori
factor
r
cost
howev
substanti
variat
self
report
cost
estim
adequ
explain
cluster
explanatori
variabl
consid
regress
begin
discuss
paramet
assumpt
underli
simul
includ
construct
cost
po
distribut
defin
differ
simul
scenario
turn
step
undertaken
random
sampl
estim
total
expect
vaccin
r
cost
preclin
phase
ii
estim
total
vaccin
r
cost
preclin
phase
clinic
phase
ii
depend
number
preclin
clinic
eid
vaccin
candid
current
avail
r
pipelin
combin
two
set
random
input
paramet
gener
expect
phase
ii
associ
r
cost
output
cost
r
phase
po
r
phase
set
cost
r
phase
paramet
reli
selfreport
cost
estim
provid
vaccin
develop
survey
appendix
categor
two
group
lower
bound
group
cost
estim
base
product
develop
previou
licensur
trackrecord
upper
bound
group
cost
estim
base
product
develop
licensur
trackrecord
group
took
selfreport
cost
estim
creat
rang
cost
rang
boundari
defin
lowest
highest
report
cost
estim
respect
group
assign
equal
probabl
cost
construct
discret
distribut
cost
r
phase
figur
present
cumul
distribut
function
lower
upper
bound
vaccin
r
cost
r
phase
figur
demonstr
vaccin
project
cost
use
simul
scenario
fall
final
assumpt
base
ran
simul
statist
independ
paramet
po
r
phase
paramet
drawn
differ
dataset
identifi
literatur
review
independ
cost
paramet
therefor
like
assum
correl
po
r
phase
possibl
signific
variabl
po
may
relat
name
target
diseas
type
technolog
use
given
prophylact
vaccin
standard
regulatori
pathway
exist
eid
diseasespecif
failur
risk
assum
across
diseas
moreov
r
failur
due
platform
technolog
issu
preclin
phase
ii
assum
spill
vaccin
candid
even
develop
organ
howev
phase
iii
licensur
includ
analysi
assumpt
would
longer
hold
po
correl
coeffici
vaccin
candid
make
use
platform
technolog
would
calcul
integr
explicitli
simul
analysi
methodolog
calcul
total
vaccin
r
cost
base
combin
eid
vaccin
r
pipelin
data
simul
paramet
stepwis
manner
step
specifi
valu
number
vaccin
candid
r
phase
preclin
phase
phase
ii
avail
step
step
scenario
draw
randomli
iter
rang
cost
us
valu
distribut
function
known
determin
base
cost
associ
bring
current
number
eid
vaccin
candid
next
phase
develop
call
stage
gate
ie
phase
vaccin
candid
current
preclin
phase
develop
phase
ii
vaccin
candid
current
phase
phase
iii
vaccin
candid
current
phase
ii
step
scenario
draw
randomli
iter
rang
po
valu
triangular
cumul
distribut
function
known
determin
probabl
success
advanc
current
number
eid
vaccin
candid
next
phase
develop
stage
gate
step
step
data
assumpt
support
simul
paramet
describ
allow
us
estim
simul
model
number
success
phase
ii
outcom
expect
invest
current
vaccin
r
pipelin
eid
associ
total
portfolio
cost
achiev
phase
ii
outcom
given
current
eid
vaccin
r
pipelin
known
appendix
present
detail
overview
rational
design
stochast
optim
methodolog
begin
descript
formul
model
turn
discuss
solut
method
conclud
present
probabilist
sensit
analysi
find
associ
differ
stage
model
wherea
simulationbas
scenario
analys
provid
analyt
depth
highlight
scenario
limit
capac
demonstr
optim
solut
minim
optim
object
eid
vaccin
r
optim
techniqu
provid
insight
priorit
r
invest
minim
maxim
object
function
subject
analyt
constraint
exceed
moreov
simultan
consider
multipl
candid
project
key
aspect
manag
new
product
develop
pipelin
pharmaceut
r
manag
sever
stochast
model
approach
propos
address
varieti
problem
multistag
simulationoptim
model
identifi
optim
number
project
requir
deliv
pharmaceut
r
output
maxim
econom
valu
discreteev
simul
combin
mix
integ
linear
program
optim
structur
order
activ
within
pharmaceut
r
portfolio
mix
integ
linear
program
use
simul
real
option
valuat
employ
determin
optim
size
structur
pharmaceut
r
portfolio
discreteev
simul
combin
genet
algorithm
base
optim
procedur
optim
select
order
pharmaceut
r
project
maxim
econom
valu
minim
probabl
econom
loss
approach
discreteev
simul
combin
effici
frontier
analysi
identifi
optim
pharmaceut
r
portfolio
differ
level
risk
budget
constraint
simulationoptim
techniqu
propos
incorpor
mix
integ
linear
program
optim
schedul
alloc
resourc
pharmaceut
r
pipelin
relat
approach
propos
clinic
trial
schedul
valu
maxim
pharmaceut
event
stochast
simul
model
use
multiobject
genet
algorithm
optim
structur
sequenc
pharmaceut
r
portfolio
minim
time
minim
risk
maxim
econom
valu
r
other
use
multistag
stochast
program
knapsack
decomposit
algorithm
optim
structur
pharmaceut
r
pipelin
multirang
robust
optim
techniqu
pharmaceut
r
project
select
number
simulationoptim
techniqu
simultan
portfolio
manag
manufactur
capac
plan
summar
literatur
sever
simulationoptim
techniqu
time
depend
optim
new
product
develop
pipelin
schedul
program
techniqu
recent
review
use
chanc
constrain
optim
optim
pharmaceut
develop
process
uncertainti
literatur
demonstr
stochast
optim
provid
meaning
priorit
insight
new
product
develop
presenc
uncertainti
given
inher
riski
natur
vaccin
r
stochast
model
approach
like
repres
realist
reflect
uncertain
expect
pharmaceut
r
process
howev
evid
predominantli
provid
theoret
approach
hypothet
yet
challeng
sophist
problem
may
relat
directli
address
reallif
situat
common
limit
literatur
studi
attempt
overcom
optim
model
describ
stochast
nonsmooth
mix
integ
program
snpmip
problem
key
paramet
model
provid
main
part
studi
tabl
provid
definit
elabor
sever
assumpt
undertaken
mix
integ
problem
concern
optim
problem
least
variabl
restrict
integ
introduc
discontinu
object
function
search
space
feasibl
solut
nonsmooth
optim
mean
optim
problem
deriv
inform
object
variabl
use
determin
direct
object
function
increas
decreas
creat
nonconvex
space
mani
potenti
feasibl
solut
given
natur
snpmip
problem
unlik
possibl
solut
calcul
global
optim
solut
found
snpmip
problem
tradit
optim
techniquessuch
linear
nonlinear
convex
programmingbreak
either
due
irregular
structur
search
space
search
becom
comput
intract
case
evolutionari
comput
approach
offer
robust
flexibl
altern
optim
problem
solv
solut
longer
determinist
ie
singl
point
estim
repres
global
optimum
solut
without
uncertainti
probabilist
ie
rang
estim
repres
multipl
like
optim
solut
uncertainti
gener
introduct
evolutionari
algorithm
overview
genet
algorithm
model
optim
found
elsewher
literatur
although
genet
evolutionari
algorithm
develop
independ
sinc
share
overal
approach
gener
candid
solut
problem
via
random
select
evolut
solut
nearoptim
solut
seri
fitnessbas
evolutionari
step
see
figur
illustr
despit
small
differ
technic
detail
genet
evolutionari
algorithm
gener
treat
part
famili
evolutionari
comput
method
figur
illustr
evolutionari
algorithm
start
randomli
draw
popul
candid
solut
algorithm
learn
adapt
search
even
better
optima
relat
current
solut
composit
popul
candid
solut
chang
adapt
support
random
chang
mutat
origin
parent
popul
candid
solut
yield
new
candid
solut
children
may
may
improv
previou
solut
throughout
process
evolutionari
algorithm
select
fittest
elimin
least
fit
member
popul
candid
solut
evolutionari
algorithm
continu
drive
toward
everbett
least
evernew
solut
comparison
previous
gener
solut
constrain
rule
design
serv
stop
condit
comput
process
includ
maximum
comput
time
allow
number
fit
iter
allow
maximum
time
allow
fit
iter
take
place
without
improv
current
solut
minim
differ
new
versu
previou
set
solut
latter
condit
also
known
converg
critic
indic
whether
optim
nearoptim
solut
met
howev
prematur
convergenceth
loss
divers
set
solut
quickli
search
processcan
lead
solut
nearoptim
avoid
number
optim
run
permit
given
optim
problem
make
use
evolutionari
algorithm
need
substanti
although
good
practic
agreement
minimum
threshold
number
optim
run
requir
evolutionari
algorithm
reach
converg
near
optim
solut
studi
ran
optim
problem
stage
model
assum
minimum
optim
would
suffici
minim
risk
earli
converg
problem
stage
model
differ
model
paramet
consist
zero
close
zero
th
th
percentil
valu
consecut
optim
beyond
minimum
run
assum
converg
solut
found
evolutionari
program
increasingli
employ
solv
stochast
optim
problem
simulationoptim
techniqu
pharmaceut
r
manag
problem
demonstr
evid
also
referenc
earlier
appendix
basic
idea
behind
simul
optim
set
valu
decis
variabl
consid
model
perform
one
simul
iter
constraint
object
depend
uncertainti
model
use
measur
decid
set
valu
tri
next
decis
variablesand
process
repeat
new
simul
conduct
step
optim
overal
benefit
simulationoptim
treatment
optim
outcom
probabilist
outcom
account
uncertainti
signific
limit
associ
techniqu
number
comput
step
requir
deriv
solut
grow
exponenti
number
variabl
constraint
includ
optim
problem
instanc
cumul
comput
time
solut
across
stage
model
hour
total
stage
ask
much
invest
would
need
progress
least
one
vaccin
end
phase
iia
eid
given
current
new
preclin
vaccin
candid
made
avail
tabl
demonstr
probabl
associ
least
one
phase
iia
outcom
per
eid
total
cost
less
us
billion
us
billion
less
across
scenario
like
cost
rang
achiev
minimum
phase
iia
target
eid
us
billion
follow
us
billion
rang
us
billion
rang
respect
final
tabl
demonstr
varianc
expect
phase
iia
outcom
strongli
correl
varianc
po
r
phase
particular
po
phase
ii
varianc
associ
portfolio
cost
posit
correl
cost
po
r
phase
howev
varianc
expect
cost
sensit
preclin
phase
ii
cost
follow
po
r
phase
sensit
analysi
demonstr
wherea
zero
phase
ii
outcom
unlik
expect
phase
ii
outcom
beyond
one
phase
iibiii
readi
candid
depend
po
moreov
wherea
likelihood
portfolio
cost
us
billion
us
billion
achiev
minimum
prepared
r
target
eid
interest
close
zero
like
cost
rang
depend
relationship
po
r
phase
cost
associ
experi
indirect
cost
vaccin
develop
instanc
scenario
low
cost
associ
high
po
distribut
number
vaccin
candid
would
need
fund
per
high
poshigh
cost
scenario
overal
portfolio
cost
would
drop
us
billion
us
million
billion
rang
wherea
scenario
high
cost
associ
low
po
distribut
number
vaccin
candid
would
need
fund
per
low
poslow
cost
scenario
howev
portfolio
cost
would
increas
us
billion
us
billion
rang
explain
appendix
statist
independ
assum
cost
po
distribut
r
phase
moreov
assum
selfreport
cost
estim
statist
independ
number
vaccin
candid
identifi
r
pipelin
per
section
varianc
portfolio
cost
associ
phase
iia
outcom
posit
correl
cost
po
distribut
r
phase
given
varianc
like
amplifi
varianc
observ
report
cost
pipelin
data
quantifi
uncertainti
associ
simulationoptim
analysi
determin
extent
variat
observ
data
amplifi
analyt
process
estim
varianc
product
follow
two
variabl
number
vaccin
candid
per
r
phase
selfreport
cost
estim
per
r
phase
use
follow
formula
x
number
candid
pipelin
consid
selfreport
cost
estim
compar
standard
deviat
standard
deviat
associ
posadjust
cost
estim
simulationoptim
per
tabl
main
articl
standard
deviat
cost
singl
vaccin
candid
advanc
end
phase
iia
simul
model
assum
po
lower
standard
deviat
observ
selfreport
cost
data
standard
deviat
cost
one
vaccin
candid
success
advanc
end
phase
iia
simulationoptim
deviat
increasingli
standard
deviat
observ
selfreport
data
number
vaccin
candid
consid
start
earlier
phase
develop
po
distribut
r
phase
taken
account
comparison
standard
deviat
see
appendix
tabl
line
sensit
analysi
suggest
amplif
uncertainti
measur
eid
vaccin
r
cost
sole
base
object
function
simulationoptim
model
minimum
phase
iia
outcom
impact
po
distribut
r
phase
number
vaccin
candid
requir
per
r
phase
achiev
object
sourc
uncertainti
amplif
analysi
relat
variat
observ
selfreport
cost
data
